Cargando…

Current Progress of RNA Aptamer-Based Therapeutics

Aptamers are single-stranded nucleic acids that specifically recognize and bind tightly to their cognate targets due to their stable three-dimensional structure. Nucleic acid aptamers have been developed for various applications, including diagnostics, molecular imaging, biomarker discovery, target...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiehua, Bobbin, Maggie L., Burnett, John C., Rossi, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486975/
https://www.ncbi.nlm.nih.gov/pubmed/23130020
http://dx.doi.org/10.3389/fgene.2012.00234
_version_ 1782248425182461952
author Zhou, Jiehua
Bobbin, Maggie L.
Burnett, John C.
Rossi, John J.
author_facet Zhou, Jiehua
Bobbin, Maggie L.
Burnett, John C.
Rossi, John J.
author_sort Zhou, Jiehua
collection PubMed
description Aptamers are single-stranded nucleic acids that specifically recognize and bind tightly to their cognate targets due to their stable three-dimensional structure. Nucleic acid aptamers have been developed for various applications, including diagnostics, molecular imaging, biomarker discovery, target validation, therapeutics, and drug delivery. Due to their high specificity and binding affinity, aptamers directly block or interrupt the functions of target proteins making them promising therapeutic agents for the treatment of human maladies. Additionally, aptamers that bind to cell surface proteins are well suited for the targeted delivery of other therapeutics, such as conjugated small interfering RNAs (siRNA) that induce RNA interference (RNAi). Thus, aptamer-siRNA chimeras may offer dual-functions, in which the aptamer inhibits a receptor function, while the siRNA internalizes into the cell to target a specific mRNA. This review focuses on the current progress and therapeutic potential of RNA aptamers, including the use of cell-internalizing aptamers as cell-type specific delivery vehicles for targeted RNAi. In particular, we discuss emerging aptamer-based therapeutics that provide unique clinical opportunities for the treatment various cancers and neurological diseases.
format Online
Article
Text
id pubmed-3486975
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-34869752012-11-05 Current Progress of RNA Aptamer-Based Therapeutics Zhou, Jiehua Bobbin, Maggie L. Burnett, John C. Rossi, John J. Front Genet Genetics Aptamers are single-stranded nucleic acids that specifically recognize and bind tightly to their cognate targets due to their stable three-dimensional structure. Nucleic acid aptamers have been developed for various applications, including diagnostics, molecular imaging, biomarker discovery, target validation, therapeutics, and drug delivery. Due to their high specificity and binding affinity, aptamers directly block or interrupt the functions of target proteins making them promising therapeutic agents for the treatment of human maladies. Additionally, aptamers that bind to cell surface proteins are well suited for the targeted delivery of other therapeutics, such as conjugated small interfering RNAs (siRNA) that induce RNA interference (RNAi). Thus, aptamer-siRNA chimeras may offer dual-functions, in which the aptamer inhibits a receptor function, while the siRNA internalizes into the cell to target a specific mRNA. This review focuses on the current progress and therapeutic potential of RNA aptamers, including the use of cell-internalizing aptamers as cell-type specific delivery vehicles for targeted RNAi. In particular, we discuss emerging aptamer-based therapeutics that provide unique clinical opportunities for the treatment various cancers and neurological diseases. Frontiers Media S.A. 2012-11-02 /pmc/articles/PMC3486975/ /pubmed/23130020 http://dx.doi.org/10.3389/fgene.2012.00234 Text en Copyright © 2012 Zhou, Bobbin, Burnett and Rossi. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Genetics
Zhou, Jiehua
Bobbin, Maggie L.
Burnett, John C.
Rossi, John J.
Current Progress of RNA Aptamer-Based Therapeutics
title Current Progress of RNA Aptamer-Based Therapeutics
title_full Current Progress of RNA Aptamer-Based Therapeutics
title_fullStr Current Progress of RNA Aptamer-Based Therapeutics
title_full_unstemmed Current Progress of RNA Aptamer-Based Therapeutics
title_short Current Progress of RNA Aptamer-Based Therapeutics
title_sort current progress of rna aptamer-based therapeutics
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486975/
https://www.ncbi.nlm.nih.gov/pubmed/23130020
http://dx.doi.org/10.3389/fgene.2012.00234
work_keys_str_mv AT zhoujiehua currentprogressofrnaaptamerbasedtherapeutics
AT bobbinmaggiel currentprogressofrnaaptamerbasedtherapeutics
AT burnettjohnc currentprogressofrnaaptamerbasedtherapeutics
AT rossijohnj currentprogressofrnaaptamerbasedtherapeutics